Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01913561
Other study ID # HWG001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2013
Est. completion date August 31, 2017

Study information

Verified date August 2018
Source HealthWatch Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.

The electrodes are dry, textile ECG electrodes. The garment is designed to position the electrodes in the appropriate anatomical locations, without any special guidance. The dry electrodes are made from unique yarns with silver embedded into the garment using a proprietary technique developed by HealthWatch (HW)that obviates the need for skin preparation or the application of fluids. The garment can be connected to any standard ECG device available in the hospitals.

The purpose of this study is to evaluate the safety and effectiveness of the Master Caution Garment for continuous monitoring of ECG signal compared to standard gel electrodes.

The following endpoints will be evaluated in subjects participating in the study:

Primary:

Compare the quality of the ECG signal of HW textile electrodes compared to gel electrodes using standard ECG devices.

Secondary:

Compare the quality of the ECG signal of HW textile electrodes compared to gel electrodes when event is detected by the ECG devices.


Description:

Part A - ECG in Rest

1. In the beginning of the study, the following parameters will be measured and documented in the CRF: blood pressure, body temperature, respiratory rate and oxygen saturation in the blood.

2. The patient will be dressed with the Master Caution Garment and connected to a 12 lead ECG device. The procedure takes 5 minutes including data printing.

3. A twelve lead ECG with gel electrodes will be done and data printed. The procedure takes 5 minutes. The patient will stay connected to the monitor for the following hour.

4. After an hour the data from the gel electrodes will be printed again.

5. The patient will be dressed again with the Master Caution Garment and connected to a 12 lead ECG device. The procedure takes 5 minutes including data printing.

6. The following parameters will be compared between the gel ECG and the Garment ECG:

- Heart Rate (HR)

- P wave width and amplitude

- QRS complex width and amplitude

- T wave width and amplitude

- RR interval

- PR interval

- QT interval

Part B - ECG in motion

1. In the beginning of the study, the following parameters will be measured : blood pressure, body temperature, respiratory rate and oxygen saturation in the blood.

2. Four (4) gel electrodes will be placed on the patient on the following places - Left Arm (LA), Right Arm (RA), Left Leg (LL) and Right Leg (RL).

3. The patient will be dressed with the Master Caution Garment (MCG)on the 4 gel electrodes that were already placed.

4. The same 4 electrodes in the garment LA, RA, LL and RL will be connected to a standard of care ECG device.

5. The 4 gel electrodes will be connected to a standard of care ECG device.

6. The ECG devices will be recording the ECG signal from the two sets of electrodes for 24 hours.

Every hour in the first 6 hours the data will be printed from both devices. In every event detected the data will be printed from both devices. the data will be evaluated for quality comparison between the gel and the textile electrodes using the hospital ECG device.

7. In first 6 hours for every hour and for each event detected by either the gel electrodes or the MCG textile electrodes the following parameters shell be evaluated at the end of the study from the hospital ECG printouts for the Master Caution Garment and for the gel electrodes:

- Heart Rate (HR)

- P wave width and amplitude

- QRS complex width and amplitude

- T wave width and amplitude

- RR interval

- PR interval

- QT interval After first 6 hours for each event detected by either the gel electrodes or the MCG textile electrodes the above mentioned parameters shell be evaluated at the end of the study from the hospital ECG printouts for the Master Caution Garment and for the gel electrodes.

The goal of the current study is to evaluate the safety of the MCG and compare ECG signals from the Master Caution Garment with the ECG signals from gel electrodes.

This is a prospective, comparative study.

For each time interval and each event detected by the ECG devices, the analysis will determine its category as follows:

1. Blinded cardiologist's assessment whether at that time interval the patient suffered from a disorder. This assessment will be based on hospital's recorded data with the gel electrodes.

2. The Master Caution Garment result for that time interval will be categorized as follows:

- True Positive (TP) = MCG Alert was right (based on GS)

- False Positive (FP) = MCG Alert was wrong

- True Negative (TN) = No MCG Alert when indeed alert was not necessary

- False Negative (FN) = No MCG Alert but there was a disorder case


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date August 31, 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Age>18 years.

- Suspected for arrhythmia or have evidence of arrhythmia disorder.

- Needs continuous, in-hospital ECG monitoring.

- Ability to give informed consent.

Exclusion Criteria:

- Patients with known allergy to silver.

- Patients with recent trauma to chest wall.

- Pregnant or lactating woman.

- Patients with chest deformity precluding placement of the garment.

- Patients participating in another ongoing trial.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Master Caution Garment
Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG. The electrodes are dry, textile ECG electrodes.
ECG gel electrodes
Standard gel electrodes that are been in use in hospital for ECG monitoring.

Locations

Country Name City State
Israel Rambam medical center Haifa

Sponsors (1)

Lead Sponsor Collaborator
HealthWatch Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary From the ECG record collect the Heart Rate HR. 0,1,2,3,4,5,6 hours and in each arrythemia event detected durring 24 hours from the start of the ECG recording.
Primary From the ECG record collect the P Wave width (sec.) and the amplitude (mV). 0,1,2,3,4,5,6 hours and in each arrythemia event detected durring 24 hours from the start of the ECG recording.
Primary From the ECG record collect the QRS Complex width (sec.) and the amplitude (mV). 0,1,2,3,4,5,6 hours and in each arrythemia event detected durring 24 hours from the start of the ECG recording.
Primary From the ECG record collect the T Wave width (sec.) and the amplitude (mV). 0,1,2,3,4,5,6 hours and in each arrythemia event detected durring 24 hours from the start of the ECG recording.
Primary From the ECG record collect the RR Interval width (sec.). 0,1,2,3,4,5,6 hours and in each arrythemia event detected durring 24 hours from the start of the ECG recording.
Primary From the ECG record collect the PR Interval width (sec.). 0,1,2,3,4,5,6 hours and in each arrythemia event detected durring 24 hours from the start of the ECG recording.
Primary From the ECG record collect the QT Interval width (sec.). 0,1,2,3,4,5,6 hours and in each arrythemia event detected durring 24 hours from the start of the ECG recording.
See also
  Status Clinical Trial Phase
Recruiting NCT05048602 - Drug-induced Brugada Syndrome Research Database
Completed NCT05053243 - Clinical Validation of the AliveCor Kardia 12L and 6L Devices N/A
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT01396226 - A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients Phase 2
Completed NCT00756886 - Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study N/A
Terminated NCT00624520 - Mental Stress Reduction in Defibrillator Patients Phase 3
Terminated NCT00721149 - NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study Phase 3
Completed NCT00510029 - Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously Phase 1
Completed NCT00578617 - Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial N/A
Active, not recruiting NCT00135174 - Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study N/A
Completed NCT00119847 - Electrophysiological Effects of Late PCI After MI N/A
Completed NCT00035490 - Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators Phase 3
Completed NCT00023556 - Genetic Architecture of Heart Disease in Rural Brazil N/A
Completed NCT01076361 - Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study N/A
Completed NCT00004560 - Public Access Defibrillation (PAD) Community Trial Phase 3
Recruiting NCT00138931 - Genetics of Cardiovascular and Neuromuscular Disease
Completed NCT01076348 - Model 4965 Post-Approval Study
Completed NCT00622453 - Arrhythmias in Myotonic Muscular Dystrophy N/A
Completed NCT00000531 - Antiarrhythmics Versus Implantable Defibrillators (AVID) Phase 3
Completed NCT00000480 - Multicenter Unsustained Tachycardia Trial (MUSTT) Phase 3